Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Aalter – page 58

1 353 clinical trials in Aalter, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Aalter at a glance
1 353
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 353 trials in Aalter

Open in trial search

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Hypertriglyceridaemia

Not recruiting

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Hot flush

Not recruiting

Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Cardiac amyloidosis

Not recruiting

Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Gastric cancer+1

Not recruiting

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Study on Bepranemab for Patients with Early Alzheimer's Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bepranemab
  • Sponsor:UCB Biopharma

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Aalter

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) medication management for patients with chronic digestive conditions.

  • Functional Dyspepsia
  • Heartburn Management
  • Gastric Reflux

These primary care studies evaluate various deprescribing strategies, including on-demand PPI use and alternative treatments with alginate formulations, aiming to optimize long-term medication management for patients.

02 Primary Care Innovation

Research exploring optimal medication reduction strategies in primary care settings, with a focus on improving patient outcomes and reducing unnecessary long-term medication use.

  • Medication Management
  • Deprescribing Protocols
  • Treatment Optimization

The studies compare different approaches to medication reduction, evaluating their effectiveness in maintaining symptom control while minimizing long-term medication dependency.

03 Digestive Health Research

Clinical investigations targeting chronic digestive conditions and their management through various therapeutic approaches.

  • Acid Suppression Therapy
  • Alternative Treatment Methods
  • Patient-Centered Care

These trials aim to establish evidence-based guidelines for transitioning patients from long-term acid suppression therapy to more appropriate treatment regimens.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.